摘要
目的:探讨白蛋白结合型紫杉醇联合卡铂对晚期非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)患者血清肿瘤标志物水平的影响。方法:选取2023年1月至2024年8月我院收治的70例晚期NSCLC患者作为研究对象,以随机数字表法分为观察组和对照组,各35例。对照组采用紫杉醇+卡铂治疗,观察组采用白蛋白结合型紫杉醇+卡铂治疗。比较两组治疗效果、肿瘤标志物、炎症因子以及毒副反应发生情况。结果:观察组疾病控制率明显高于对照组(P<0.05)。治疗前,两组肿瘤标志物、炎症因子水平无明显差异(P>0.05)。治疗后,两组肿瘤标志物、炎症因子水平均明显降低,且观察组明显低于对照组(P<0.05)。观察组毒副反应发生率明显低于对照组(P<0.05)。结论:与常规紫杉醇+卡铂治疗相比,晚期NSCLC患者采用白蛋白结合型紫杉醇联合卡铂效果更好,利于减轻炎症反应,降低肿瘤标志物水平,提升化疗安全性,值得广泛应用。
Objective:To investigate the effect of albumin bound paclitaxel combined with carboplatin on serum tumor marker levels in patients with advanced non-small cell lung cancer(NSCLC).Methods:Select 70 patients with advanced NSCLC admitted to our hospital from January 2023 to August 2024 and group them using a random number table method.35 cases in the control group were treated with paclitaxel+carboplatin,while 35 cases in the observation group were treated with albumin bound paclitaxel+carboplatin.Compare the treatment efficacy,tumor markers,inflammatory factors,and incidence of toxic side effects between two groups.Results:The disease control rate of the observation group was higher than that of the control group(P<0.05).There was no significant difference in tumor markers and inflammatory factors between the two groups before treatment(P>0.05).After treatment,the levels of tumor markers and inflammatory factors decreased in both groups,and the observation group had even lower levels(P<0.05).The incidence of toxic side effects in the observation group was lower than that in the control group(P<0.05).Conclusion:Compared with conventional paclitaxel+carboplatin treatment,the combination of albumin bound paclitaxel and carboplatin has better efficacy in advanced NSCLC patients,which is beneficial for reducing inflammation,lowering tumor marker levels,and improving chemotherapy safety.It is worth widely applying.
作者
程何龙
何志光
Cheng He-long;He Zhi-guang(Emergency Pharmacy,Nanyang Central Hospital,Nanyang 473000,Henan,China)
